PDCD1 and nonpapillary renal cell carcinoma: However, a research study showed that standard pre-treatment T cell receptor (TCR) clonality could predict clinical response to anti-PD-1 therapy in ccRCC [39], while others observe a considerable variation of TCR clonality across disease stages of ccRCC [27].